• In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data.

• Together, these vaccine milestones highlight Pfizer's ongoing role in infectious disease prevention across both seasonal COVID-19 protection and addressing unmet need in Lyme disease.

• Next, we'll examine how progress on Pfizer's Lyme disease vaccine program could influence its longer-term investment narrative and risk profile.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe that its broad late stage pipeline and cost savings can offset patent expirations and slower legacy brands. The Depo Provera settlement program, while a legal overhang, does not appear to change the core near term catalyst, which still centers on execution in oncology and vaccines, or the key risk around pricing pressure and upcoming loss of exclusivity on major drugs.

The EMA's validation of Pfizer and Valneva's Lyme disease vaccine application is most relevant here, because it sits on the same infectious disease platform story as COVID updates while contrasting with the Depo Provera litigation. If regulators ultimately clear PF 07307405, it could become a meaningful proof point for Pfizer's vaccine pipeline at the same time that legal settlements and pricing reforms test its ability to protect margins.

Yet against this progress, investors should also be aware that unresolved legal and pricing pressures could still...

Read the full narrative on Pfizer (it's free!)

Pfizer's narrative projects $54.9 billion in revenue and $9.2 billion in earnings by 2029. This implies a 4.6% yearly revenue decline and a $1.7 billion earnings increase from $7.5 billion today.

Uncover how Pfizer's forecasts yield a $29.19 fair value , a 4% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming Pfizer's revenue could fall to about US$50.6 billion by 2029, and see the Depo Provera legal overhang as reinforcing their concern that pipeline wins alone may not fully offset pricing pressure and patent losses; as a reader, you should know that these more pessimistic views sit in sharp contrast to the base case and may shift again as the settlement terms and vaccine outcomes become clearer.